Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fingernail moons may reveal who responds to breast cancer therapy

NCT ID NCT07590570

Knowledge-focused Sponsor: Wenjin Yin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether the small white moons at the base of fingernails (lunula) can predict how well breast cancer patients respond to chemotherapy before surgery. Researchers will track 188 patients to see if lunula status is linked to tumor disappearance and side effects. The goal is to find a simple, non-invasive way to personalize treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
neoadjuvant therapy (chemotherapy before surgery)
What this could lead to
If successful, this could help doctors predict which breast cancer patients will benefit most from neoadjuvant therapy, personalizing treatment.
What could go wrong
This is an observational study, not a treatment trial. The link between lunula status and outcomes is unproven and may not lead to any change in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 188 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jan 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Breast cancer patients who have received or plan to receive neoadjuvant therapy.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older * Pathologically confirmed invasive primary breast cancer * Patients who have received or are scheduled to receive neoadjuvant therapy Exclusion Criteria: * De novo stage IV breast cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer invasive are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer invasive

Contacts and locations

Locations

  • Renji Hospital, School of Medicine, Shanghai Jiaotong University

    Shanghai, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.